Agenus Inc. (NASDAQ:AGEN) Lifted to “Buy” at BidaskClub

Agenus Inc. (NASDAQ:AGEN) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Monday, July 24th.

Several other equities analysts have also issued reports on AGEN. Maxim Group reissued a “buy” rating and issued a $7.00 price target on shares of Agenus in a research note on Sunday, April 23rd. HC Wainwright set a $5.00 price target on Agenus and gave the company a “hold” rating in a research note on Saturday, May 6th. Zacks Investment Research raised Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Wednesday, July 5th. Finally, ValuEngine lowered Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $5.88.

Shares of Agenus (NASDAQ:AGEN) opened at 3.55 on Monday. Agenus has a one year low of $3.20 and a one year high of $7.49. The firm’s 50-day moving average is $4.30 and its 200 day moving average is $3.90. The firm’s market capitalization is $353.98 million.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The firm had revenue of $4.21 million for the quarter, compared to analyst estimates of $6.66 million. During the same period in the previous year, the firm earned ($0.33) earnings per share. The company’s revenue was down 36.1% compared to the same quarter last year. Equities research analysts predict that Agenus will post ($1.13) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Agenus Inc. (NASDAQ:AGEN) Lifted to “Buy” at BidaskClub” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/08/12/agenus-inc-nasdaqagen-stock-rating-upgraded-by-bidaskclub-updated-updated.html.

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC raised its position in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock worth $140,000 after buying an additional 23,689 shares during the last quarter. OxFORD Asset Management LLP purchased a new position in shares of Agenus during the second quarter worth $141,000. AQR Capital Management LLC purchased a new position in shares of Agenus during the fourth quarter worth $143,000. American International Group Inc. raised its stake in Agenus by 7.1% in the first quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,984 shares during the last quarter. Finally, Quotient Investors LLC raised its stake in Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock worth $177,000 after buying an additional 3,800 shares during the last quarter. 42.78% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

What are top analysts saying about Agenus Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agenus Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit